**Supplementary Table 1**

|  |  |
| --- | --- |
| **Inclusion** | **Exclusion** |
| Bronchopulmonary Dysplasia,  Hyaline Membrane Disease,  Respiratory Distress Disorder | Meta-analyses, \*in-silico\* analyses, or re-analysis of previously published data |
| Accepted methodologies | Candidate *in-vivo* or *in-vitro* transcriptomic or proteomic studies (defined as those investigating < 50 genes) |
|  | Candidate gene association studies |
| **Human** | |
| *In vivo, in vitro*, primary human cells and tissues | Term babies, Children, Adults |
| Any/all treatment administered to patients before sample collection |  |
| **Animal** | |
| Mammals (non-human) |  |
| *In vivo* studies |  |
| Hyperoxia, induced IUGR, LPS treatment |  |

Supplementary Table 1: Inclusion and exclusion criteria for MAIC analysis